Live Breaking News & Updates on Infectious Diseases Immunology At Australia Griffith University

‘I never heard from them again’: A missed vaccine opportunity has left Chinese companies scrambling
We’re sorry, this service is currently unavailable. Please try again later.
Dismiss
By Bruce Einhorn
Save
Normal text size
Advertisement
The call came early in the COVID-19 pandemic. Drew Weissman, an infectious diseases professor at the University of Pennsylvania and an expert in messenger RNA, received a query from a Chinese company interested in using the new technology to make a vaccine against the coronavirus.
mRNA, which effectively turns the body’s cells into tiny vaccine-making factories, has since become the breakout star of the COVID era, underpinning shots made by Moderna and the Pfizer/BioNTech partnership which have been among the most effective in fighting the disease. Before COVID hit, though, the experimental science had yet to receive regulatory approval for use against any illness - let alone against the mysteriou ....

United States , United Kingdom , Surbhi Gupta , Daiichi Sankyo , Marcha Fox , Feng Duojia , Joe Biden , Nigel Mcmillan , Lusong Luo , Cansino Biologics , George Fu Gao , China Association Of Vaccines , China Global Television Network , Sinopharm Group , School Of Molecular Sciences , Infectious Diseases Immunology At Australia Griffith University , Sinovac Biotech , China National Biotec , Chinese Centre For Disease , Precision Nanosystems Inc , China National Biotec Group , University Of Pennsylvania , Chulalongkorn University , Chinese Centre , Disease Control , Communist Party Backed ,